NCT01233375已完成2 期
A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 13
- 主要终点
- Disease Control Rate (CR, PR, or SD) using RECIST 1.1
研究概览
简要总结
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.
详细描述
Pancreatic tumors with low hENT1 expression may show less benefit from gemcitabine compared with those with higher expression of this nucleoside transporter. Nonclinical studies indicate that CO-1.01, a gemcitabine derivative, is effective independent of such transporters. Thus patients with low or no meaningful expression of hENT1 who failed to respond to gemcitabine might derive benefit from CO1.01 before needing alternative (combination) chemotherapy. Furthermore, the PK profiles of CO-1.01 and gemcitabine are dissimilar and this may confer additional clinical benefit on CO1.01.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Gemcitabine-refractory metastatic ductal adenocarcinoma of the pancreas
- •At least 1 measurable lesion according to RECIST 1.1 criteria
- •Computerized tomography (CT) scan ≤ 28 days prior to CO-1.01
- •First-line treatment included at least 3 doses of gemcitabine (as monotherapy or combination therapy) with the last dose administered at least 2 weeks prior to CO 1.01
- •Radiological best response of disease progression after 1st-line treatment (no radiological stable disease or better allowed at any time)
- •Patients who experienced progressive disease during (neo)-adjuvant gemcitabine-based therapy are also eligible
- •Patients who have completed previous adjuvant therapy without progression, then subsequently have a radiological best response of disease progression on 1st line gemcitabine for metastatic disease are eligible
- •No hENT1 expression in primary or metastatic tumor sample, confirmed with IHC by a core pathology laboratory prior to study entry also eligible
- •Performance Status (ECOG) 0 or 1
- •Age ≥18 years
- •Palliative radiotherapy (if administered) ≥2 weeks prior to CO-1.01
- •Adequate hematological and biological function, with no residual gemcitabine-related toxicity
- •Written consent on an Institutional Review Board (IRB)-approved IC Form prior to any study-specific evaluation
排除标准
- •Patients who have had stable disease, partial response or complete response to first line gemcitabine-based therapy
- •First-line chemotherapy regimen that does not contain gemcitabine
- •First-line treatment discontinued due to intolerable gemcitabine-induced toxicity
- •Second or subsequent line therapy for advanced disease. Prior exposure to CO-1.01 or prior randomization in a protocol studying CO-1.01 (e.g.,Protocol CO-101-001)
- •Tumor that cannot be evaluated for hENT1 expression or that has hENT1 staining in >50% of cells
- •Symptomatic brain metastases
- •Concomitant treatment with prohibited medications (e.g., concurrent anticancer therapy including other chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate], or immunotherapy) ≤14 days prior to CO-1.01
- •Exploratory laparotomy, palliative (e.g., bypass) surgery, or other procedures are not allowed <14 days prior to CO-1.01 administration; stenting procedures are permissible at any time prior to dosing; in all cases, the patient must be sufficiently recovered and stable
- •History of allergy to gemcitabine or eggs
- •Females who are pregnant or breastfeeding
- •Refusal to use adequate contraception for fertile patients (females and males during the study and for 6 months after the last dose of CO-1.01)
- •Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, psychiatric disturbance, uncontrolled intercurrent illness including active infection, arterial thrombosis, or symptomatic pulmonary embolism)
- •Any other reason for which the investigator considers the patient should not participate in the study
研究组 & 干预措施
CO-1.01
Experimental
干预措施: CO-1.01 (Drug)
结局指标
主要结局
Disease Control Rate (CR, PR, or SD) using RECIST 1.1
时间窗: Every 8 weeks until disease progression
次要结局
- Overall Response Rate (ORR)(Every 8 weeks)
- CA 19-9 response rate(Every 4 weeks)
- Progression-free survival (PFS)(Every 8 weeks)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(Every week)
- Overall survival (OS)(3, 6, 9, and 12 months)
- Median progression-free survival(3, 6, 9, and 12 months)
- Median overall survival(3, 6, 9, and 12 months)
- Duration of response(Every 8 weeks)
研究者
研究点 (13)
Loading locations...
相似试验
终止
1 期
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaMelanomaNCT03878719Pfizer1
已完成
1 期
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal CancersSolid TumorNCT05162755Institut de Recherches Internationales Servier41
进行中（未招募）
2 期
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationMetastatic Colorectal CancermCRCNCT05127759Shanghai Henlius Biotech25
已完成
1 期
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)Lymphoma, Non-HodgkinNCT05844956Dizal Pharmaceuticals17
进行中（未招募）
2 期
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell CarcinomaNCT05054439Sichuan Baili Pharmaceutical Co., Ltd.45